— Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing. Adams joined the Seattle-based biotech giant more than three… Read More
Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. The company said it was shutting a program focused on… Read More
After announcing plans last summer to build its manufacturing facility in California, Sana Biotechnology has changed course. The cell and gene therapy company will now develop an 80,000 square foot… Read More
Biotech is coming off an epic few years. The sector soared during the pandemic, with venture capital investment and IPO volumes hitting all-time highs. But recently stock valuations have plummeted,… Read More
Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr… Read More
When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells,… Read More
In a region better known for its tech startups and legions of software engineers, it’s biotech companies that have helped lead a recent IPO boom in the state of Washington,… Read More
Sana Biotechnology, a young and fast-growing Seattle-based biotech, has chosen the San Francisco Bay Area as the site for its new biomanufacturing facility. The gene editing and cell therapy company… Read More
Human stem cell scientists have long dreamed of repairing damaged hearts, but have been stymied by research showing that the cells yield irregular heartbeats in laboratory animals. A new genetic engineering… Read More
Editor’s note: Sana Biotechnology priced shares on Wednesday evening, raising $587.5 million. See full story here. Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of… Read More
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle… Read More
Here’s what we’re talking about on the GeekWire Podcast this week: Seattle’s tech community just reached a new milestone: 10 unicorns, privately held companies valued at more than $1 billion.… Read More
The unicorn — that supposed elusive creature of the startup world — is becoming a bit more commonplace in these parts. There are now 10 unicorn startups valued at $1… Read More
Here’s what we’re talking about on the GeekWire Podcast this week. Despite the pandemic, funding for Pacific Northwest tech startups remains robust in the first half of 2020. In fact,… Read More
Editor’s note: The GeekWire Awards are now virtual on July 23. Watch live below. Technology is increasingly influencing the science of health, and the delivery of health care. Scientists and… Read More
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing. Backed by ARCH Venture Partners, Flagship… Read More